Compare $EGRX vs $LTRN | Chartloom

Compare

$EGRX vs $LTRN

Eagle Pharmaceuticals Inc · Lantern Pharma Inc

EGRX

Eagle Pharmaceuticals Inc

LTRN

Lantern Pharma Inc

Compare $EGRX vs $LTRN

Comparing Eagle Pharmaceuticals Inc and Lantern Pharma Inc

EGRXEagle Pharmaceuticals Inc

LTRNLantern Pharma Inc

EGRXEagle Pharmaceuticals Inc

Market cap

$13M

P/E (TTM)

1.06x

Forward P/E (NTM)

0.25x

Forward P/S (NTM)

0.05x

Rev growth (TTM)

-5.4%

YTD performance

185.3%

52W performance

49.2%

FCF yield

-74.5%

LTRNLantern Pharma Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-73.9%

52W performance

-82.3%

FCF yield

-135.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

EGRX

LTRN

Detailed metrics comparison

EGRX

Eagle Pharmaceuticals Inc

LTRN

Lantern Pharma Inc

Market Cap

EGRX$13M

LTRN$10M

Enterprise Value

EGRX$67M

LTRN$4M

Price

EGRX$0.97

LTRN$0.81

P/E Ratio

EGRX1.06x

LTRNN/A

P/S Ratio

EGRX0.05x

LTRN0.00x

EV/Sales

EGRX0.26x

LTRN0.00x

EV/EBITDA

EGRX1.07x

LTRN0.00x

P/B Ratio

EGRX0.05x

LTRN3.19x

P/FCF Ratio

EGRXN/A

LTRNN/A

EV/FCF

EGRX-7.18x

LTRN-0.26x

PEG Ratio

EGRXN/A

LTRNN/A

Forward P/E (NTM)

EGRX0.25x

LTRNN/A

Forward P/S (NTM)

EGRX0.05x

LTRNN/A

Revenue (TTM)

EGRX$258M

LTRN$0

Revenue Growth (YoY)

EGRX-5.4%

LTRNN/A

Forward Rev Growth

EGRX0.0%

LTRN0.0%

Gross Margin (TTM)

EGRX69.9%

LTRN0.0%

Operating Margin (TTM)

EGRX14.0%

LTRN0.0%

EBITDA Margin (TTM)

EGRX24.5%

LTRN0.0%

Net Margin (TTM)

EGRX4.7%

LTRN0.0%

FCF Margin (TTM)

EGRX-3.6%

LTRNN/A

Net Income (TTM)

EGRX$12M

LTRN$-19M

FCF (TTM)

EGRX$-9M

LTRN$-14M

EPS (TTM)

EGRX$0.92

LTRN-$1.50

ROE (TTM)

EGRX5.0%

LTRN-19835.0%

ROA (TTM)

EGRX3.0%

LTRN-18428.0%

ROIC (TTM)

EGRX3.9%

LTRN-19835.0%

Cash

EGRX$15M

LTRN$7M

Debt

EGRX$70M

LTRN$0

Net Cash/Debt

EGRX$-55M

LTRN$7M

Current Ratio (TTM)

EGRX2.16x

LTRN1.96x

Quick Ratio (TTM)

EGRX1.52x

LTRN1.70x

Debt/Equity (TTM)

EGRX0.28x

LTRN0.00x

Debt/Assets (TTM)

EGRX0.0%

LTRN0.0%

Interest Coverage (TTM)

EGRXN/A

LTRNN/A

Net Debt/EBITDA (TTM)

EGRX0.00x

LTRN0.00x

Beta

EGRX0.88

LTRN2.42

52W Performance

EGRX49.2%

LTRN-82.3%

YTD Performance

EGRX185.3%

LTRN-73.9%

% from 52W High

EGRX-74.9%

LTRN-82.7%

% from 52W Low

EGRX88081.8%

LTRN6.9%

Asset Turnover (TTM)

EGRX0.64x

LTRN0.00x

FCF Yield (TTM)

EGRX-74.5%

LTRN-135.8%

Earnings Yield (TTM)

EGRX96.0%

LTRN-179.9%

Dividend Yield (TTM)

EGRXN/A

LTRNN/A

Rule of 40

EGRX-9.0

LTRN0.0

EV/GP/RG

EGRXN/A

LTRNN/A

Ticker research

View EGRX research View LTRN research

Metric	EGRX Eagle Pharmaceuticals Inc	LTRN Lantern Pharma Inc
Market & Valuation
Market Cap	$13M	$10M
Enterprise Value	$67M	$4M
Price	$0.97	$0.81
P/E Ratio	1.06x	N/A
P/S Ratio	0.05x	0.00x
EV/Sales	0.26x	0.00x
EV/EBITDA	1.07x	0.00x
P/B Ratio	0.05x	3.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.18x	-0.26x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	0.25x	N/A
Forward P/S (NTM)	0.05x	N/A
Revenue & Growth
Revenue (TTM)	$258M	$0
Revenue Growth (YoY)	-5.4%	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	69.9%	0.0%
Operating Margin (TTM)	14.0%	0.0%
EBITDA Margin (TTM)	24.5%	0.0%
Net Margin (TTM)	4.7%	0.0%
FCF Margin (TTM)	-3.6%	N/A
Net Income (TTM)	$12M	$-19M
FCF (TTM)	$-9M	$-14M
EPS (TTM)	$0.92	-$1.50
ROE (TTM)	5.0%	-19835.0%
ROA (TTM)	3.0%	-18428.0%
ROIC (TTM)	3.9%	-19835.0%
Financial Health
Cash	$15M	$7M
Debt	$70M	$0
Net Cash/Debt	$-55M	$7M
Current Ratio (TTM)	2.16x	1.96x
Quick Ratio (TTM)	1.52x	1.70x
Debt/Equity (TTM)	0.28x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.88	2.42
52W Performance	49.2%	-82.3%
YTD Performance	185.3%	-73.9%
% from 52W High	-74.9%	-82.7%
% from 52W Low	88081.8%	6.9%
Efficiency & Yields
Asset Turnover (TTM)	0.64x	0.00x
FCF Yield (TTM)	-74.5%	-135.8%
Earnings Yield (TTM)	96.0%	-179.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-9.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View EGRX research	View LTRN research

Valuation

P/E Ratio

EGRX

1.06x

P/S Ratio

LTRN

0.00x

EGRX

0.05x

EV/FCF

EGRX

-7.18x

LTRN

-0.26x

Growth & revenue

Revenue Growth TTM

EGRX

-5.4%

Forward Revenue Growth

EGRX

0.0%

LTRN

0.0%

Profitability & performance

Gross Margin

EGRX

69.9%

LTRN

0.0%

ROE

EGRX

5.0%

LTRN

-19835.0%

FCF Yield %

EGRX

-74.5%

LTRN

-135.8%

52-Week Performance

EGRX

49.2%

LTRN

-82.3%

Detailed metrics comparison

EGRX

Eagle Pharmaceuticals Inc

LTRN

Lantern Pharma Inc

Market Cap

EGRX$13M

LTRN$10M

Enterprise Value

EGRX$67M

LTRN$4M

Price

EGRX$0.97

LTRN$0.81

P/E Ratio

EGRX1.06x

LTRNN/A

P/S Ratio

EGRX0.05x

LTRN0.00x

EV/Sales

EGRX0.26x

LTRN0.00x

EV/EBITDA

EGRX1.07x

LTRN0.00x

P/B Ratio

EGRX0.05x

LTRN3.19x

P/FCF Ratio

EGRXN/A

LTRNN/A

EV/FCF

EGRX-7.18x

LTRN-0.26x

PEG Ratio

EGRXN/A

LTRNN/A

Forward P/E (NTM)

EGRX0.25x

LTRNN/A

Forward P/S (NTM)

EGRX0.05x

LTRNN/A

Revenue (TTM)

EGRX$258M

LTRN$0

Revenue Growth (YoY)

EGRX-5.4%

LTRNN/A

Forward Rev Growth

EGRX0.0%

LTRN0.0%

Gross Margin (TTM)

EGRX69.9%

LTRN0.0%

Operating Margin (TTM)

EGRX14.0%

LTRN0.0%

EBITDA Margin (TTM)

EGRX24.5%

LTRN0.0%

Net Margin (TTM)

EGRX4.7%

LTRN0.0%

FCF Margin (TTM)

EGRX-3.6%

LTRNN/A

Net Income (TTM)

EGRX$12M

LTRN$-19M

FCF (TTM)

EGRX$-9M

LTRN$-14M

EPS (TTM)

EGRX$0.92

LTRN-$1.50

ROE (TTM)

EGRX5.0%

LTRN-19835.0%

ROA (TTM)

EGRX3.0%

LTRN-18428.0%

ROIC (TTM)

EGRX3.9%

LTRN-19835.0%

Cash

EGRX$15M

LTRN$7M

Debt

EGRX$70M

LTRN$0

Net Cash/Debt

EGRX$-55M

LTRN$7M

Current Ratio (TTM)

EGRX2.16x

LTRN1.96x

Quick Ratio (TTM)

EGRX1.52x

LTRN1.70x

Debt/Equity (TTM)

EGRX0.28x

LTRN0.00x

Debt/Assets (TTM)

EGRX0.0%

LTRN0.0%

Interest Coverage (TTM)

EGRXN/A

LTRNN/A

Net Debt/EBITDA (TTM)

EGRX0.00x

LTRN0.00x

Beta

EGRX0.88

LTRN2.42

52W Performance

EGRX49.2%

LTRN-82.3%

YTD Performance

EGRX185.3%

LTRN-73.9%

% from 52W High

EGRX-74.9%

LTRN-82.7%

% from 52W Low

EGRX88081.8%

LTRN6.9%

Asset Turnover (TTM)

EGRX0.64x

LTRN0.00x

FCF Yield (TTM)

EGRX-74.5%

LTRN-135.8%

Earnings Yield (TTM)

EGRX96.0%

LTRN-179.9%

Dividend Yield (TTM)

EGRXN/A

LTRNN/A

Rule of 40

EGRX-9.0

LTRN0.0

EV/GP/RG

EGRXN/A

LTRNN/A

Ticker research

View EGRX research View LTRN research

Metric	EGRX Eagle Pharmaceuticals Inc	LTRN Lantern Pharma Inc
Market & Valuation
Market Cap	$13M	$10M
Enterprise Value	$67M	$4M
Price	$0.97	$0.81
P/E Ratio	1.06x	N/A
P/S Ratio	0.05x	0.00x
EV/Sales	0.26x	0.00x
EV/EBITDA	1.07x	0.00x
P/B Ratio	0.05x	3.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.18x	-0.26x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	0.25x	N/A
Forward P/S (NTM)	0.05x	N/A
Revenue & Growth
Revenue (TTM)	$258M	$0
Revenue Growth (YoY)	-5.4%	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	69.9%	0.0%
Operating Margin (TTM)	14.0%	0.0%
EBITDA Margin (TTM)	24.5%	0.0%
Net Margin (TTM)	4.7%	0.0%
FCF Margin (TTM)	-3.6%	N/A
Net Income (TTM)	$12M	$-19M
FCF (TTM)	$-9M	$-14M
EPS (TTM)	$0.92	-$1.50
ROE (TTM)	5.0%	-19835.0%
ROA (TTM)	3.0%	-18428.0%
ROIC (TTM)	3.9%	-19835.0%
Financial Health
Cash	$15M	$7M
Debt	$70M	$0
Net Cash/Debt	$-55M	$7M
Current Ratio (TTM)	2.16x	1.96x
Quick Ratio (TTM)	1.52x	1.70x
Debt/Equity (TTM)	0.28x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.88	2.42
52W Performance	49.2%	-82.3%
YTD Performance	185.3%	-73.9%
% from 52W High	-74.9%	-82.7%
% from 52W Low	88081.8%	6.9%
Efficiency & Yields
Asset Turnover (TTM)	0.64x	0.00x
FCF Yield (TTM)	-74.5%	-135.8%
Earnings Yield (TTM)	96.0%	-179.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-9.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View EGRX research	View LTRN research